obesity pharmaceutical research 2026

Graphic: Viking SUNRISE trials of oral VK2735, two overlapping circles for the oral 68-week and injection 78-week programmes

Viking Opens SUNRISE Trials of Oral VK2735, a Bold Push With Real Hurdles

Megan Wood14 hours ago13 hours ago010 mins

Viking SUNRISE trials of oral VK2735 start in adults with obesity, with 68 weeks of treatment. How the tablet and injection programmes fit and the hurdles.